The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
Abstract
OBJECTIVE: To investigate the efficacy and safety of donepezil in patients with moderate to severe AD (standardized Mini-Mental State Examination [sMMSE] scores of 5 to 17; Functional Assessment Staging score < or =6 at baseline). METHODS: Two-hundred ninety patients were randomized to treatment in this 24-week, double-blind, placebo-controlled trial. Patients received either donepezil 5 mg/day for the first 28 days and 10 mg/day thereafter as per the clinician's judgment (n = 144) or placebo (n = 146). The primary outcome measure was the Clinician's Interview-Based Impression of Change with caregiver input (CIBIC+). RESULTS: Patients' mean age was 73.6 years (range 48 to 92 years). Baseline demographics were similar between the treatment groups. Least squares (LS) mean +/- SE sMMSE scores at baseline were 11.7 +/- 0.35 for the donepezil group and 12.0 +/- 0.34 for the placebo group. Patients receiving donepezil showed benefits on the CIBIC+, compared with placebo, at all visits up to week 24 (p < 0.001) and at week 24 last observation carried forward (LOCF) (p < 0.0001). All other secondary measures (including sMMSE, Severe Impairment Battery, Disability Assessment for Dementia, Functional Rating Scale, and Neuropsychiatric Inventory) showed significant differences between the groups in favor of donepezil at week 24 LOCF. Eighty-four percent of donepezil- and 86% of placebo-treated patients completed the trial. Adverse events (AE) were experienced by 83% of donepezil- and 80% of placebo-treated patients, the majority of which were rated mild in severity; 8% of donepezil- and 6% of placebo-treated patients discontinued because of AE. Laboratory and vital sign abnormalities were similar between the treatment groups. CONCLUSION: These data suggest that donepezil's benefits extend into more advanced stages of AD than those previously investigated, with very good tolerability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Caregiving and the stress process: an overview of concepts and their measures
Pearlin, L. I., Mullan, J. T., Semple, S. J., & Skaff, M. M. (1990) · The Gerontologist · doi:10.1093/geront/30.5.583 · Cited by 4,810
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · cited 2×
“Baseline cessation during trial 3 (2) 1 (1)”
BackgroundUnified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Functional Assessment Staging (FAST)
(2001) · Management of Dementia · doi:10.3109/9780203213896-33 · Cited by 1,023
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Self-citationA 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 921
Self-citationGélinas, I., Gauthier, L., McIntyre, M., & Gauthier, S. (1999) · The American Journal of Occupational Therapy · doi:10.5014/ajot.53.5.471 · Cited by 900
Self-citationRaskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 773
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.1.102 · Cited by 647
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Schmitt, F. A., Grundman, M., Thomas, R. G., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00004 · Cited by 647
The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1
Burns, A., Rossor, M., Hecker, J., Gauthier, S., Petit, H., Möller, H.-J., Rogers, S. L., & Friedhoff, L. T. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017126 · Cited by 580
Self-citationCholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease
Davis, K. L. (1999) · JAMA · doi:10.1001/jama.281.15.1401 · Cited by 492
Severe Impairment Battery: A Neuropsychological Test for Severely Demented Patients
Panisset, M. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540130067012 · Cited by 323
Schneider, L. S., Olin, J. T., Doody, R. S., Clark, C. M., Morris, J. C., Reisberg, B., Ferris, S. H., Schmitt, F. A., Grundman, M., & Thomas, R. G. (1997) · Alzheimer Disease · doi:10.1007/978-1-4612-4116-4_64 · Cited by 303
The Cholinergic Hypothesis of Neuropsychiatric Symptoms in Alzheimer's Disease
Cummings, J. L., & Back, C. (1998) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199821001-00009 · Cited by 274
MCHORNEY, C. A., & WARE, J. E. (1995) · Medical Care · doi:10.1097/00005650-199501000-00002 · Cited by 260
Gilmor, M. L., Erickson, J. D., Varoqui, H., Hersh, L. B., Bennett, D. A., Cochran, E. J., Mufson, E. J., & Levey, A. I. (1999) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19990906)411:4<693::aid-cne13>3.0.co;2-d · Cited by 239
The Spectrum of Behavioral Responses to Cholinesterase Inhibitor Therapy in Alzheimer Disease
Mega, M. S., Masterman, D. M., O'Connor, S. M., Barclay, T. R., & Cummings, J. L. (1999) · Archives of Neurology · doi:10.1001/archneur.56.11.1388 · Cited by 236
Research advances in Alzheimer's disease and related disorders
Iqbal, K., & Disorders, R. (1995) · Wiley eBooks · Cited by 228
Cerebral Blood Flow Correlates of Apathy in Alzheimer Disease
Craig, A. H., Cummings, J. L., Fairbanks, L., Itti, L., Miller, B. L., Li, J., & Mena, I. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550110056012 · Cited by 223
Knopman, D. S., Knapp, M. J., Gracon, S. I., & Davis, C. S. (1994) · Neurology · doi:10.1212/wnl.44.12.2315 · Cited by 213
(1995) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.7.4.476 · Cited by 198
Early-life risk factors and the development of Alzheimer’s disease
Moceri, V. M., Kukull, W. A., Emanuel, I., van Belle, G., & Larson, E. B. (2000) · Neurology · doi:10.1212/wnl.54.2.415 · Cited by 184
Net economic costs of dementia in Canada.
Østbye, T., & Crosse, E. (1994) · Europe PMC (PubMed Central) · Cited by 181
Cholinergic deficits contribute to behavioral disturbance in patients with dementia
Minger, S. L., Esiri, M. M., McDonald, B., Keene, J., Carter, J., Hope, T., & Francis, P. T. (2000) · Neurology · doi:10.1212/wnl.55.10.1460 · Cited by 176
Patterns of Caring for People with Dementia in Canada The Canadian Study of Health and Aging
Lindsay, J. (1994) · Canadian Journal on Aging / La Revue canadienne du vieillissement · doi:10.1017/s0714980800006334 · Cited by 171
The Physiology and Pharmacology of Melatonin in Humans
Geoffriau, M., Brun, J., Chazot, G., & Claustrat, B. (1998) · Hormone Research in Paediatrics · doi:10.1159/000023160 · Cited by 164
Schmitt, F. A., Ashford, W., Ernesto, C., Saxton, J. A., Schneider, L., Clark, C. M., Ferris, S. H., Mackell, J. A., Schafer, K. A., & Thal, L. J. (1997) · PubMed · Cited by 111
Assessing Alzheimer Severity With a Global Clinical Scale
Ashford, J. W., Kumar, V., Barringer, M., Becker, M. A., Bice, J., Ryan, N., & Vicari, S. K. (1992) · International Psychogeriatrics · doi:10.1017/s1041610292000905 · Cited by 65
Torfs, K., & Feldman, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)83429-6 · Cited by 21
Self-citationWinblad (1999) · doi:10.1002/(sici)1099-1166(199902)14:2
Cited by
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
Metadata
- Authors
- Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., Whalen, E., & the Donepezil MSAD Study Investigators Group*
- Venue
- Neurology
- Published
- 2001-08-28
- Volume
- 57
- Issue
- 4
- Pages
- 613-620
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2030079540
- Cited by
- 601
- References
- 39
- FWCI
- 31.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.